Novel strategy to adapt simian-human immunodeficiency virus e1 carrying env from an rv144 volunteer to rhesus macaques: Coreceptor switch and final recovery of a pathogenic virus with exclusive r5 tropism

• Main Authors: Hanna B. Scinto, Sandeep Gupta, Swati Thorat, Muhammad M. Mukhtar, Anthony Griffiths, Jennifer Delgado, Elizabeth Plake, Hemant K. Vyas, Amanda Strickland, Siddappa N. Byrareddy, David C. Montefiori, Celia LaBranche, Ranajit Pal, Jim Treece, Sharon Orndorff, Maria Grazia Ferrari, Deborah Weiss, Agnes Laurence Chenine, Robert McLinden, Nelson Michael, Jerome H. Kim, Merlin L. Robb, Supachai Rerks-Ngarm, Punnee Pitisuttithum, Sorachai Nitayaphan, Ruth M. Ruprecht
• Other Authors: Duke University Medical Center
• Format: Article
• Published: 2019
• Subjects: Agricultural and Biological Sciences; Immunology and Microbiology
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/44732
• Institution: Mahidol University

©2018 American Society for Microbiology. The phase III RV144 human immunodeficiency virus (HIV) vaccine trial conducted in Thailand remains the only study to show efficacy in decreasing the HIV acquisition risk. In Thailand, circulating recombinant forms of HIV clade A/E (CRF01_AE) predominate; in s...